文献速递产科

剖宫产时使用自体血回输:随机对照试验的荟萃分析

Use of cell salvage at the time of cesarean delivery: a meta-analysis of randomized controlled trials.
PubMed 文献 · Am J Obstet Gynecol MFM · 2023-12-16

本荟萃分析纳入5项随机对照试验(n=3361),比较剖宫产时自体血回输与标准治疗的围术期结局。结果显示自体血回输显著降低异体血输血率(OR 0.32,95%CI 0.23-0.46),血红蛋白下降幅度无变化(MD -0.77,95%CI -1.67至-0.14),输血反应和住院时间无差异,1685例接受自体血回输者中无羊水栓塞病例。

要点

  • 剖宫产时自体血回输可显著降低异体血输血需求(OR 0.32,95%CI 0.23-0.46)。
  • 血红蛋白下降幅度、输血反应及住院时间与标准治疗无显著差异。
  • 1685例接受自体血回输的患者中未报告羊水栓塞病例。

核心结论

  • 剖宫产时使用自体血回输降低了异体血输注的总体需求,且不增加并发症风险,包括无羊水栓塞病例。

研究设计与样本

  • 研究类型为随机对照试验的荟萃分析,纳入5项随机对照试验,共3361例患者,比较剖宫产时自体血回输与标准治疗。
  • 检索数据库包括Scopus、PubMed、Cochrane Central Register of Controlled Trials、Ovid Medline和clinicaltrials.gov,检索时间从数据库建库至2023年10月。
  • 由两位作者独立提取数据,采用系统综述和荟萃分析优先报告条目(PRISMA)指南进行数据提取和质量评估。
  • 主要结局为异体血输血率和血红蛋白水平变化;次要结局包括输血反应、羊水栓塞和住院时间。
  • 结果以加权均数差或风险比及相应95%置信区间汇总,异质性采用Higgins I²测量。

主要发现

  • 与标准治疗相比,术中自体血回输组接受异体血输血的风险显著降低(OR 0.32,95%CI 0.23-0.46)。
  • 血红蛋白下降幅度在自体血回输组与标准治疗组间无显著变化(MD -0.77,95%CI -1.67至-0.14)。
  • 输血反应在两组间无差异(OR 0.56,95%CI 0.06-5.59)。
  • 住院时间在两组间无差异(MD -1.90,95%CI -4.85至1.06)。
  • 1685例接受自体血回输的患者中未报告羊水栓塞病例。

临床怎么用

  • 原文结论认为剖宫产时使用自体血回输可降低异体血输血需求且不增加并发症风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Excess blood loss from obstetrical hemorrhage requires transfusion of donor blood, a finite resource. Intraoperative cell salvage collects a patient's own blood that has been lost during cesarean delivery and returns it to their own circulation. We performed a meta-analysis to examine the perioperative outcomes in patients receiving cell salvage at the time of cesarean delivery. DATA SOURCES: Scopus, PubMed, Cochrane Central Register of Controlled Trials, Ovid Medline, and clinicaltrials.gov were searched from database inception through October 2023. STUDY ELIGIBILITY CRITERIA: Eligible studies included randomized controlled trials comparing the use of cell salvage to standard-of-care during cesarean delivery. METHODS: Two authors independently extracted data. Preferred Reporting Items of Systematic Reviews and Meta-Analysis guidelines were used for data extraction and quality assessment. The primary outcomes were the rate of donor blood transfusion and change in hemoglobin level. The secondary outcomes included transfusion reaction, amniotic fluid embolism, and length of hospital stay. Results were summarized as weighted mean difference or risk ratio with associated 95% confidence intervals. Heterogeneity was measured using Higgins I2. RESULTS: A total of 5 randomized controlled trials (n=3361) comparing cell salvage to standard care during cesarean delivery met the inclusion criteria. Primary analysis showed a significant decrease in receiving allogeneic blood transfusion with intraoperative cell salvage use vs standard care (odds ratio, 0.32; 95% confidence interval, 0.23-0.46), with no change in hemoglobin drop (mean difference, -0.77; 95% confidence interval, -1.67 to -0.14). The secondary outcomes showed no difference in transfusion reaction (odds ratio, 0.56; 95% confidence interval, 0.06-5.59), and length of hospital stay (mean difference, -1.90; 95% confidence interval, -4.85 to 1.06). No cases of amniotic fluid embolism were reported among the 1685 patients who received cell salvage. CONCLUSION: Use of cell salvage during cesarean delivery reduced the overall need for allogeneic blood transfusion without increasing the risk of complications, including no cases of amniotic fluid embolism.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Iyer NS, Khanuja K, Roman A, et al. Use of cell salvage at the time of cesarean delivery: a meta-analysis of randomized controlled trials. Am J Obstet Gynecol MFM. 2023. PMID: 38109996. doi:10.1016/j.ajogmf.2023.101257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。